Szela Mary T 4

What Happened Mary T. Szela, CEO, President and a director of TriSalus Life Sciences, received 3,990 shares in an acquisition reported for 2026-06-30. The shares were acquired at $3.87 per share, for a total value of $15,441. This was an award/acquisition through the issuer's Employee Stock Purchase Plan rather than an open-market trade.

Key Details

• Transaction date: 2026-06-30; Filing date: 2026-07-01 (appears timely).
• Transaction type: Grant / award / acquisition (code A) via Employee Stock Purchase Plan.
• Price per share: $3.87; Total value: $15,441.
• Shares owned after transaction: Not disclosed in this filing.
• Footnote: F1 — Shares were acquired through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
• No indication of an immediate sale or cashless exercise.

Context Employee Stock Purchase Plan acquisitions are common for company insiders and are typically routine compensation or benefit transactions; they are exempted under Rule 16b-3 and do not by themselves indicate a change in insider sentiment. Because this is a purchase/acquisition rather than a sale, some investors view it as a modestly positive sign, but the dollar amount ($15.4k) is relatively small.